MACK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MACK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Merrimack Pharmaceuticals's Enterprise Value is $-20.36 Mil. Merrimack Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.26 Mil. Therefore, Merrimack Pharmaceuticals's EV-to-EBIT for today is 9.01.
The historical rank and industry rank for Merrimack Pharmaceuticals's EV-to-EBIT or its related term are showing as below:
During the past 13 years, the highest EV-to-EBIT of Merrimack Pharmaceuticals was 9.01. The lowest was -20.41. And the median was -1.89.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Merrimack Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $-29.48 Mil. Merrimack Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.26 Mil. Merrimack Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 7.66%.
The historical data trend for Merrimack Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merrimack Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBIT | Get a 7-Day Free Trial | -1.21 | -15.59 | -14.61 | -65.99 | -79.77 |
Merrimack Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-EBIT | Get a 7-Day Free Trial | -71.37 | -69.36 | -68.76 | -79.77 | 13.05 |
For the Biotechnology subindustry, Merrimack Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Merrimack Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Merrimack Pharmaceuticals's EV-to-EBIT falls into.
Merrimack Pharmaceuticals's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | -20.362 | / | -2.259 | |
= | 9.01 |
Merrimack Pharmaceuticals's current Enterprise Value is $-20.36 Mil.
Merrimack Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merrimack Pharmaceuticals (NAS:MACK) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Merrimack Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) | = | EBIT | / | Enterprise Value (Q: Mar. 2024 ) |
= | -2.259 | / | -29.475314 | |
= | 7.66 % |
Merrimack Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $-29.48 Mil.
Merrimack Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Merrimack Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Eric Andersen | director, other: See Remarks | 1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404 |
Gary L Crocker | director, officer: President | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
Noah G. Levy | director, other: See Remarks | 60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165 |
Ana Radeljevic | director | 2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467 |
Ulrik B. Nielsen | director | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
Russell T Ray | director | 2525 DUPONT DR, IRVINE CA 92612 |
Newtyn Capital Partners, Lp | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
Ledo Capital, Llc | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
Newtyn Te Partners, Lp | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
Newtyn Partners, Lp | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
Western Standard Partners Qp, L.p. | other: See Remarks | 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036 |
Western Standard Partners Lp | other: See Remarks | 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036 |
Western Standard Llc | other: See Remarks | 5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036 |
Newtyn Management, Llc | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
22nw Gp, Inc. | 10 percent owner, other: See Explanation of Responses | 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107 |
From GuruFocus
By PRNewswire PRNewswire • 08-22-2019
By Business Wire Business Wire • 11-05-2020
By Business Wire Business Wire • 03-11-2021
By PRNewswire PRNewswire • 10-19-2018
By Business Wire Business Wire • 05-05-2022
By Business Wire Business Wire • 08-04-2022
By Business Wire • 08-03-2023
By Business Wire Business Wire • 05-08-2020
By Business Wire Business Wire • 11-03-2022
By PRNewswire PRNewswire • 11-01-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.